Focal Onset Seizures Clinical Trial
Official title:
A Phase 2A, Multicenter, Open-label Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy
This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine if RAP-219 works and is safe in patients with Refractory Focal Epilepsy.
This is a Phase 2A, proof-of-concept, multi-center, open-label study designed to evaluate the efficacy, safety, tolerability, and PK/PD relationship of RAP-219 in adult participants with refractory focal epilepsy. The activity of RAP-219 will be assessed in approximately 20 participants treated with the RNS® system. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05614063 -
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures
|
Phase 3 | |
| Recruiting |
NCT05716100 -
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
|
Phase 3 | |
| Completed |
NCT04836559 -
A Study to Investigate JNJ-40411813 in Combination With Levetiracetam or Brivaracetam in Epilepsy
|
Phase 2 | |
| Terminated |
NCT05473442 -
Study of EQU-001 for Uncontrolled Focal Onset Seizures
|
Phase 2 |